Search PubMed⌕ Search

Biomedical subjects

M Sámal

Publications and source records attributed to M Sámal.

30 records · Page 2Linked to original sources
PubMed1982

Ceruloplasmin in Hodgkin's disease.

In 56 patients with Hodgkin's disease different clinical and histological stages the activity of polyphenoloxidase was repeatedly examined in the course of the disease as an indicator of serum ceruloplasmin concentration. In untreated patients the ceruloplasmin concentration was on average twice as high as in healthy controls. Repeated examinations made in the course of the disease demonstrated a good correlation of the values with the clinical condition of the patient, with the exception of some terminal stages and conditions following repeated chemotherapy, when liver damage was expected. The decrease to control levels in the course of therapy indicated the onset of remission. In contrast, increased levels indicated progression of the disease and necessity of treatment prolongation. Excluding intercurrent infections, higher ceruloplasmin levels above those found at remission were a clear sign of the progression. The correlation of ceruloplasmin values and erythrocyte sedimentation rate (1 h) was highly significant. The diagnostic and prognostic value of ceruloplasmin and/or serum copper determination is discussed.

Blood Sedimentation↗
PubMed1981

Phagocytic activity of peripheral blood leukocytes in patients with Hodgkin's disease.

On the basis of a simple examination of the phagocytic activity of leukocytes of the peripheral blood., with the help of the yeast cells Saccharomyces cerevisiae, we determined the functional ability of leukocytes in untreated patients with the Hodgkin's disease, in the course of the primary chemotherapy, during the complete remission and in the relapse of the disease. In all the periods we found only changes in the absolute number of phagocytic cells, corresponding to the changes in the leukocyte count (increased numbers in untreated patients and in relapse, decreased number in the course of the chemotherapy). The value of the phagocytic and activity indices in untreated patients were only moderately reduced. In the course of chemotherapy there was a more remarkable drop of the phagocytic activity only in the first half of the treatment series. In the complete remission the phagocytic activity values were normal. We did not observe significant differences between clinical stages of the Hodgkin's disease in any group. Our results correspond to the clinical course of the disease (absence of infectious complications) in the patients followed. The presented conclusions do not concern bactericidal ability of leukocytes, which is not reflected by the test method used. The test described here does not provide more data for monitoring the clinical course and chemotherapy of Hodgkin's disease than do routine examinations of the erythrocyte sedimentation and white blood count.

Female↗
PubMed1981

Interpretation of clinical symptoms in Hodgkin's disease.

The finding of general symptoms in Hodgkin's disease is accepted as bad prognostic sign and expression of disease activity. Results of clinical and histological classification analysis indicate the possibility of different interpretation of the presence and absence of symptoms in generalized disease. Asymptomatic generalized disease can be prognostically more serious than that of symptomatic one as it may express immunological tolerance of the tumor or acquired depression of defensive mechanisms. This conclusion is supported by preliminary data on survival of our patients in given classification groups.

Hodgkin Disease↗
PubMed1980

Individual changes of DNA catabolite excretion in the course of antitumor therapy of Hodgkin's disease.

In patients with morbus Hodgkin, treated primarily by the actino- and chemotherapy, the excretion was followed of DNA catabolites (deoxycytidine, deoxyuridine, thymidine and their sum) in the course of the therapy. The dynamics was studied of changes in the time interval of interest and attention was paid to its relation to the clinical and histological type of disease and to the successful character of the therapy defined by reaching a complete remission. The group of patients as a whole was characterized by an increased excretion of catabolites in the time interval of interest. No dependence was demonstrated between the catabolite excretion and extent of the disease similarly as between the excretion and successful character of the therapy. The dynamics of the changes in the time intervals of interest was neither remarkably nor continuously increased or decreased. The test of the excretion of pyrimidine deoxyribonucleosides possesses sufficient sensitivity for demonstrating laws in relation to the therapy during group evaluation. With respect to individual variability of values of particular patients and to the absence of the relations mentioned above the test is not suitable to indicate the individual response to the anticancer therapy.

Cyclophosphamide↗